OncoGenex Technologies

OncoGenex Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies that address treatment resistance in cancer patients using antisense based drugs. Custirsen, the company’s lead antisense drug that blocks clusterin, has completed Phase I and Phase II clinical trials in protstate cancer patients. The company is traded on the NASDAQ under the symbol OXGI.

Investors

Research Corporation Technologies invested in OncoGenex through Milestone Medica Corporation (MMC) in Canada. RBC Technology Ventures and RCT created MMC in 1998 to invest in product development opportunities derived from Canadian biomedical research.

Inventors/Founders

Martin Gleave, Ph.D., University of British Columbia